  Most neurovascular innovations have been introduced by using case series followed by observational studies. A better approach would be a pragmatic randomized trial. Two important aspects of trial design , patient selection and randomized allocation , remain poorly understood. We discuss the role trial methodology can play in the protection of patients being offered innovative treatments.